Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy

Hematology/Oncology Clinics of North America

Volumn 12, Issue 1, 1998, Pages 31-80

  Kantarjian, H M ^a   Giles, F J ^a   O'Brien, S M ^a   Talpaz, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CYTARABINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; HYDROXYUREA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETINOIC ACID; TALLIMUSTINE; TOPOTECAN; ZIDOVUDINE;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL PROTOCOL; DIARRHEA; DISEASE COURSE; DRUG RESPONSE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKEMIA REMISSION; LUNG TOXICITY; PATHOPHYSIOLOGY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0031934179     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70496-2     Document Type: Article

References (230)

1. G. Alimena E. Morra M. Lazzarino Interferon alpha-2b as therapy for Ph′-positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration Blood 72 1988 642
2. N. Allan S. Richards P. Shepherd UK Medical Research Council randomized multicenter trial of interferon-αn1 for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response Lancet 345 1995 1392
3. B. Anger F. Porzsolt R. Leichtle A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia Blut 58 1989 275
4. S.H. Antin Graft-versus-leukemia: No longer an epiphenomenon Blood 82 1993 2273
5. J.F. Apperley F. Mauro J.M. Goldman Bone marrow transplantation for chronic myeloid leukaemia in chronic phase: Importance of graft-versus-leukaemia effect Br J Haematol 69 1988 239
6. C. Arthur D. Ma Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia Acta Haematol 89 suppl 1 1993 15
7. C.K. Arthur A. Mijovic E. Dannie Management of chronic myeloid leukaemia in pregnancy Journal of Obstetrics and Gynaecology 11 1991 396
8. K. Atkinson J. Biggs A. Concannon Second marrow transplants for recurrence of haematological malignancy Bone Marrow Transplant 1 1986 159
9. M.R. Baer H. Ozer F.A. Foon Interferon-α therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia Br J Haematol 81 1992 167
10. B. Bär A. Schattenberg E. Mensink Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation J Clin Oncol 11 1993 513
11. M. Barnett C. Eaves G. Phillips Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study Blood 84 1994 724
12. A. Barrett Y. Jiang Immune responses to chronic myeloid leukemia Bone Marrow Transplant 9 1992 305
13. C. Bartram de Klein A. A. Hagemeijer Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia Nature 306 1983 277
14. P. Beatty C. Anasetti J. Hansen Marrow transplantation from unrelated donors for treatment of hematologic malignancies: Effect of mismatching for one HLA locus Blood 81 1993 249
15. D. Beelen U. Graeven A. Elmaagacli Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome–positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome Blood 85 1995 2981
16. Y. Ben-Neriah G.Q. Daley A.M. Mes-Masson The chronic myelogenous leukemia specific p210 protein is the product of the bcr/abl hybrid gene Science 223 1986 212
17. M. Beran S. Jeha S. O'Brien Tallimustine, an effective antileukemic agent in a SCID mouse model of adult myelogenous leukemia induces remissions in a phase I study [abstract] Blood 88 suppl 1 1996 220a
18. M. Beran H. Kantarjian S. O'Brien Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 88 1996 2473
19. R. Bhatia E. Wayner P. McGlave Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function J Clin Invest 94 1994 384
20. S. Biggs J. Szer P. Crilley Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2 Blood 80 1992 1090
21. C. Bilhou-Nabera F. Viard G. Marit Complete cytogenetic conversion in chronic myelocytic leukemia patients undergoing interferon α therapy: Follow-up with reverse polymerase chain reaction Leukemia 6 1992 595
22. C. Bilhou-Nabera P. Bernard G. Marit Serial cytogenetic studies in allografted patients with chronic myeloid leukemia Bone Marrow Transplant 9 1992 263
23. J. Boice N. Day A. Andersen Second cancer following radiation treatment for cervical cancer. An international collaboration among cancer registries J Natl Cancer Inst 74 1985 955
24. P. Borgies A. Ferrant A. Delannoy Interferon alpha induced and maintained complete remission in chronic granulocytic leukaemia in relapse after bone marrow transplantation Bone Marrow Transplant 4 1988 127
25. M. Bortin M. Horowitz P. Rowlings Report from the International Bone Marrow Transplant Registry Bone Marrow Transplant 12 1993 97
26. M. Bortin J. D'Amaro F. Bach HLA associations with leukemia Blood 70 1987 227
27. J. Brandwein I. Dube P. Laraya Maintenance of Philadelphia-chromosome–positive progenitors in long-term marrow cultures from patients with advanced chronic myeloid leukemia Leukemia 6 1992 556
28. H. Brincker Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia Scand J Haematol 29 1982 241
29. W. Brown R. Doll Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis Br Med J 2 1965 1327
30. T. Call P. Noel T. Habermann Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989 Mayo Clin Proc 69 1994 315
31. G. Canellos J. Whang-Peng V. DaVita Chronic granulocytic leukemia without the Philadelphia chromosome Am J Clin Pathol 65 1976 467
32. F. Cervantes J. Robertson C. Rozman Long-term survivors in chronic granulocytic leukaemia: A study by the International CGL Prognosis Study Group Br J Haematol 87 1994 293
33. F. Cervantes C. Rozman A multivariate analysis of prognostic factors in chronic myeloid leukemia Blood 60 1982 1298
34. R. Champlin P. McGlave Allogeneic bone marrow transplantation for chronic myeloid leukemia S.J. Forman K.G. Blume Thomas E.D. Bone Marrow Transplantation 1994 Blackwell Scientific Boston 595
35. W. Chen D. Peace K. Rovira T-cell immunity and the joining region of p210 bcr-abl protein Proc Natl Acad Sci USA 89 1992 1468
36. G. Chikkapa G. Wang D. Santella Granulocyte colony-stimulating factor induces synthesis of alkaline phosphatase in neutrophilic granulocytes of chronic myelogenous leukemia patients Leuk Res 12 1988 491
37. A. Choundhury J. Gajewski J. Liang Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome–positive chronic myelogenous leukemia Blood 89 1997 1133
38. D. Claxton A. Deisseroth M. Talpaz Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia Blood 79 1992 997
39. R. Clift C. Buckner E. Thomas Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia Blood 84 1994 4368
40. R. Clift C. Buckner E. Thomas Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide Blood 84 1994 2036
41. R. Clift F. Appelbaum E. Thomas Bone marrow transplantation for chronic myelogenous leukemia Blood 83 1994 2752
42. R. Collins O. Shpilberg W. Drobyski Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 15 1997 433
43. K. Conlon W. Urba J. Smith Exacerbation of symptoms of autoimmune disease in patients receiving alpha interferon therapy for malignant carcinoid tumors Cancer 65 1990 2237
44. J. Cortes H. Kantarjian S. O'Brien A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome–positive chronic myelogenous leukemia Leukemia 11 1997 929
45. J. Cortes H. Kantarjian S. O'Brien Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older Am J Med 100 1996 452
46. J. Cortes M. Talpaz S. O'Brien Philadelphia-chromosome negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region: Long-term follow-up results Cancer 75 1995 464
47. J. Cortes H. Kantarjian S. O'Brien GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia [abstract] Blood 88 suppl 1 1996 232a
48. J. Cortes M. Talpaz H. Kantarjian Chronic myelogenous leukemia: A review Am J Med 100 1996 555
49. L. Coulombel D. Kalousek C. Eaves Long term marrow culture reveals chromosomally normal hemopoietic progenitor cells in patients with Philadelphia-positive chronic myelogenous leukemia N Engl J Med 308 1983 1493
50. E. Cramer C. Auclair J. Hakim Metabolic activity of phagocytosing granulocytes in chronic granulocytic leukemia: Ultrastructural observation of a degranulation defect Blood 50 1977 93
51. N. Cross T. Hughes S. Mackinnon Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in chronic phase: Correlations with probability of relapse Br J Haematol 84 1993 67
52. J. Cullis Y. Jiang A. Scwarer Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation Blood 79 1992 1379
53. J. Cullis A. Scwarer T. Hughes Second transplants for patients with chronic myeloid leukemia in relapse after original transplant with T-depleted donor marrow: Feasibility of using busulfan alone for re-conditioning Br J Haematol 80 1992 33
54. I. Cunningham T. Gee M. Dowling Results of treatment of Ph′+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol) Blood 53 1979 375
55. bcr/abl gene of the Philadelphia chromosome Science 247 1990 824
56. G. Daley Van Etten R. D. Baltimore Blast crisis in a murine model of chronic myelogenous leukemia Proc Natl Acad Sci USA 88 1991 11335
57. A. De Klein Geurts van Kessel A. G. Grosfeld A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia Nature 300 1982 765
58. De Braekeleer D. Variant Philadelphia translocations in chronic myeloid leukemia Cytogenet Cell Genet 44 1987 215
59. A. Deisseroth Z. Zu D. Claxton Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow transplant in CML Blood 83 1994 3068
60. R. Dekmezian H. Kantarjian M. Keating The relevance of reticulin stain–measured fibrosis at diagnosis in chronic myelogenous leukemia Cancer 59 1987 1739
61. R. DeLage R. Soiffer K. Dear Clinical significance of bcr-abl rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia Blood 78 1991 2759
62. P. Derderian H. Kantarjian M. Talpaz Chronic myelogenous leukemia in the lymphoid blastic phase: Characteristics, treatment response, and prognosis Am J Med 94 1993 69
63. K. Dhingra R. Kurzrock H. Kantarjian Polymerase chain reaction for minimal residual disease in 20 CML patients in complete cytogenetic remission induced by interferon therapy [abstract] Blood 74 suppl 1 1989 235a
64. K. Dhingra R. Kurzrock H. Kantarjian Minimal residual disease in interferon-treated chronic myelogenous leukemia: Results and pitfalls of analysis based on polymerase chain reaction Leukemia 6 1992 754
65. J.I. Dickstein J.W. Vardiman Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes Am J Clin Pathol 99 1993 513
66. M. Djaldetti B. Padeh J. Pinkhas Prolonged remission in chronic myeloid leukemia after one course of busulfan Blood 27 1966 103
67. A. Dobrovic A. Morley R. Seshadri Molecular diagnosis of Philadelphia negative CML using the polymerase chain reaction and DNA analysis: Clinical features and course of M-bcr negative and M-bcr-positive CML Leukemia 5 1991 187
68. H. Dosik F. Rosner A. Sawitsky Acquired lipidosis: Gaucher-like cells and “blue cells” in chronic granulocytic leukemia Semin Hematol 9 1972 309
69. C. Dowding A.P. Guo J. Osterholz Interferon-α overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells Blood 78 1991 499
70. W. Drobyski C. Keevr M. Roth Donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation Blood 82 1993 2310
71. J. Dutcher L. Eudey P. Wiernik Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: A study of the Eastern Cooperative Oncology Group Leukemia 6 1992 770
72. S. Elliott K. Taylor D. Taylor Cytogenetic response to α-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location Leukemia 9 1995 946
73. T. Ernst L. Shuman M. Grossbard Treatment of the chronic phase of CML with a combined continuous infusion of homoharringtonine and cytarabine [abstract] Blood 86 suppl 1 1995 529a
74. Z. Estrov M. Talpaz T. Chou Synergistic antiproliferative effects of interferon alpha and azidothymidine in chronic myelogenous leukemia Leukemia 5 1991 101
75. Z. Estrov R. Kurzrock M. Wetzler Suppression of chronic myelogenous leukemia colony growth by IL-1 receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity Blood 78 1991 1476
76. E.Z. Ezdinli J.E. Sokal L. Crosswhite Philadelphia chromosome–positive and –negative chronic myelocytic leukemia Ann Intern Med 72 1970 175
77. 1 cells in bone marrow and 10 year remission after busulphan hypoplasia Br J Haematol 23 1972 283
78. 1 positive chronic granulocytic leukaemia Br J Haematol 39 1978 305
79. M. Freund von Wussow P. H. Diedrich Recombinant human interferon alpha-2b in chronic myelogenous leukaemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies Br J Haematol 72 1989 350
80. Y. Fujimiya W. Chang A. Bakke Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia Cancer Immunol Immunother 24 1987 213
81. M. Futaki K. Inokuchi H. Matsuoka Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in Philadelphia-positive chronic myelogenous leukemia Leuk Res 16 1992 1071
82. R. Gale E. Canaani An 8-kilobase abl RNA transcript in chronic myelogenous leukemia Proc Natl Acad Sci USA 81 1984 5648
83. D.A.G. Galton Busulphan (1,4 dimethanesulphonyloxybutane): Summary of clinical results Ann NY Acad Sci 68 1958 967
84. D. Galton Myeleran in chronic myeloid leukemia Lancet 1 1953 208
85. A. Gamis R. Haake P. McGlave Unrelated-donor bone marrow transplantation for Philadelphia chromosome–positive chronic myelogenous leukemia in children J Clin Oncol 11 1993 834
86. T.S. Ganesan F. Rassool Guo A.-P. Rearrangement of the BCR gene in Philadelphia chromosome negative chronic myeloid leukemia Blood 68 1986 957
87. F. Giles R. Aitchison D. Syndercombe-Court Recombinant alpha 2B interferon in combination with oral chemotherapy in late chronic phase chronic myeloid leukaemia Leuk Lymphoma 7 1992 99
88. F. Giles A. Jewell C. Worman Recombinant alpha interferons, thyroid irradiation and thyroid disease Acta Haematologica 85 1991 160
89. F. Giles K. Salim B. Rapoport Presenting features of chronic-phase chronic myelogenous leukemia: A comparison between Asian and French patients on the International Oncology study Group CML1 and French CML88 studies [abstract] Br J Haematol 93 suppl 2 1996 273a
90. F. Giles P. Koeffler Chronic myelogenous leukaemia Haskell C.M. Cancer Treatment, ed 4 1995 WB Saunders Philadelphia 933
91. S. Giralt H. Kantarjian M. Talpaz Treatment of chronic myelogenous leukemia Semin Oncol 22 1995 396
92. S. Giralt H. Kantarjian M. Talpaz Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia J Clin Oncol 11 1993 1055
93. S. Giralt R. Champlin Leukemia relapse after allogeneic bone marrow transplant: A review Blood 83 1994 3603
94. J.M. Goldman R. Szydlo M.M. Horowitz Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase Blood 82 1993 2235
95. G. Gomez J. Sokal A. Mittelman Splenectomy for palliation of chronic myeloid leukemia Am J Med 61 1976 14
96. M. Gordon C. Dowding G. Riley Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myeloid leukemia Nature 328 1987 342
97. A. Gratwohl J. Hermans D. Niederwieser Bone marrow transplantation for chronic myeloid leukemia: Longterm results Bone Marrow Transplant 12 1993 509
98. 1-positive chronic myelogenous leukemia Blood 51 1978 1039
99. J.D. Griffen R.F. Todd J. Ritz Differentiation patterns in the blastic phase of chronic myeloid leukemia Blood 61 1983 85
100. A. Guerrasio G. Martinelli G. Saglio Minimal residual disease status in transplanted chronic myelogenous leukemia patients: Low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants Leukemia 6 1992 507
101. F. Guilhot C. Chastang M. Michallet Interferon-alpha 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia N Engl J Med 337 1997 223
102. F. Guilhot J. Abgrall J. Harousseau A multicenter randomized study of alfa 2b interferon and hydroxyurea with or without cytosine-arabinoside in previously untreated patients with Ph+ chronic myelocytic leukemia: Preliminary cytogenetic results Leuk Lymphoma 11 suppl 1 1993 181
103. R. Hehlmann H. Heimpel J. Hasford Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia Blood 84 1994 4064
104. R. Hehlmann H. Heimpel J. Hasford Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea Blood 82 1993 398
105. P. Heubner R. Willemze A. Ganser YNKO1, an oral ara-C derivative in patients with AML, MDS, low-grade NHL and CML [abstract] Blood 81 suppl 1 1994 302a
106. C. Higano W. Raskind J. Singer Use of α interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation Blood 80 1992 1437
107. M.M. Horowitz S. Giralt R. Szydlo Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia in first chronic phase [abstract] Blood 88 suppl 1 1996 682a
108. C. Hoyle R. Gray J. Goldman Autografting for patients with CML in chronic phase: An update Br J Haematol 86 1994 76
109. T. Hughes G. Morgan P. Martiat Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse Blood 77 1991 874
110. A. Inbal E. Akstein I. Barak Cyclic leukocytosis and long survival in chronic myeloid leukemia Acta Haematol 69 1983 353
111. Italian Cooperative Study Group on Chronic Myeloid Leukaemia Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukaemia N Engl J Med 330 1994 820
112. G. Jacknow G. Frizzera K. Gajl-Peczalska Extramedullary presentation of the blast crisis of chronic myelogenous leukemia Br J Haematol 61 1985 225
113. G. Janossy R.K. Woodruff M.J. Pippard Relation of “lymphoid” phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph′ positive leukemia Cancer 43 1979 426
114. J. Jaubert P. Martiat C. Dowding The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia Br J Haematol 74 1990 30
115. Y. Jiang J. Cullis E. Kanfer T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusions to treat relapse after marrow transplantation for chronic myeloid leukaemia Bone Marrow Transplant 11 1993 133
116. D. Juan S. Hsu J. Hunter Case report of vasopressin-responsive diabetes insipidus associated with chronic myelogenous leukemia Cancer 56 1985 1468
117. H. Kantarjian T. Smith K. McCredie Chronic myelogenous leukemia: A multivariate analysis of the association of patient characteristics and therapy with survival Blood 66 1985 1326
118. H. Kantarjian R. Kurzrock M. Talpaz Philadelphia chromosome–negative chronic myelogenous leukemia and chronic myelomonocytic leukemia Hematol Oncol Clin North Am 4 1990 389
119. H. Kantarjian S. O'Brien M. Beran Results with decitabine, a hypomethylating agent, in the treatment of chronic myelogenous leukemia in accelerated or blastic phases [abstract] Blood 88 suppl 2 1996 199b
120. H. Kantarjian A. Deisseroth R. Kurzrock Chronic myelogenous leukemia: A concise update Blood 82 1993 691
121. H. Kantarjian S. O'Brien M. Keating Homoharringtonine and low-dose cytosine arabinoside combination therapy has significant activity in patients with late phase Philadelphia chromosome positive chronic myelogenous leukemia [abstract] Blood 88 suppl 1 1996 578a
122. H. Kantarjian M. Keating E. Estey Treatment of advanced stages of Philadelphia chromosome–positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine J Clin Oncol 10 1992 772
123. H. Kantarjian M. Keating M. Talpaz Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients Am J Med 83 1987 445
124. H. Kantarjian D. Dixon M. Keating Characteristics of accelerated disease in chronic myelogenous leukemia Cancer 61 1988 1441
125. H. Kantarjian T. Smith S. O'Brien Prolonged survival following achievement of cytogenetic response with alpha interferon therapy in chronic myelogenous leukemia Ann Intern Med 122 1995 254
126. H. Kantarjian T. Smith S. O'Brien Prognostic factors for response and survival with alpha interferon therapy in early chronic phase chronic myelogenous leukemia [abstract] Blood 80 suppl 1 1993 378a
127. H. Kantarjian S. O'Brien M. Keating Interferon alpha and low-dose cytosine arabinoside therapy in Philadelphia chromosome–positive chronic myelogenous leukemia [abstract] Proc ASCO 16 1997 47a
128. H. Kantarjian M. Talpaz B. Andersson High doses of cyclophosphamide, etoposide, and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia Bone Marrow Transplant 14 1994 57
129. H. Kantarjian M. Talpaz C. LeMaistre Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome–negative cells in chronic myelogenous leukemia Cancer 67 1991 2959
130. H. Kantarjian M. Keating T. Smith Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia Am J Med 88 1990 1
131. H. Kantarjian M. Talpaz M. Keating Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome–positive chronic myelogenous leukemia Cancer 68 1991 1201
132. H. Kantarjian M. Talpaz J. Hester Collection of peripheral blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy J Clin Oncol 13 1995 553
133. H. Kantarjian S. O'Brien P. Anderlini Treatment of chronic myelogenous leukemia: Current status and investigational options Blood 87 1996 3069
134. Y. Kenis P. Dustin J. Henry Action du myleran dans 22 cas de leucemie myeloide chronique Revue Francaise des Etudes Cliniques et Biologiques 1 1956 435
135. B. Kennedy K. Yarbro Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia JAMA 195 1966 1038
136. I. Khouri H. Kantarjian M. Talpaz High-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: The M.D. Anderson experience Bone Marrow Transplant 17 1996 775
137. A. Klein van Kessel A. G. Grosveld A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia Nature 300 1982 765
138. O. Kloke U. Wandl B. Opalka A prospective randomized comparison of single-agent interferon-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia Eur J Haematol 48 1992 93
139. O. Kloke N. Niederle J. Qiu Impact of interferon alpha–induced cytogenetic improvement on survival in chronic myelogenous leukemia Br J Haematol 83 1993 399
140. J. Kluin-Nelemans A. Lowagie A. Delannoy CML treated by interferon alfa-2b vs hydroxyurea alone: Preliminary report of a large multicenter randomized trial [abstract] Blood 80 suppl 1 1992 358a
141. W. Knox M. Bhavnani J. Davson Histological classification of chronic granulocytic leukaemia Clin Lab Haematol 6 1984 171
142. H. Kolb A. Schattenberg J. Goldman Graft-versus-leukemia effect of donor lymphocyte in marrow grafted patients Blood 86 1995 2041
143. J. Kolitz S. Kempin A. Schluger A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia Semin Oncol 19 suppl 9 1992 27
144. C. Koller D. Miller Preliminary observations in the therapy of myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea N Engl J Med 315 1986 1433
145. R. Kurzrock J. Gutterman M. Talpaz The molecular genetics of Philadelphia chromosome–positive leukemias N Engl J Med 319 1988 990
146. R. Kurzrock M. Blick M. Talpaz Rearrangement of the breakpoint cluster region in Philadelphia-negative chronic myelogenous leukemia Ann Intern Med 105 1986 673
147. R. Kurzrock H. Kantarjian M. Shtalrid Philadelphia chromosome–negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: A chronic myeloid leukemia with a distinct clinical course Blood 75 1990 445
148. R. Kurzrock M. Talpaz H. Kantarjian Therapy of chronic myelogenous leukemia with recombinant interferon-γ Blood 70 1987 943
149. R. Kyle R. Schwartz H. Oliner A syndrome resembling adrenal cortical insufficiency associated with long term busulfan therapy Blood 18 1961 497
150. R. Lange W. Moloney T. Yamawaki Leukemia in atomic bomb survivors. 1. General observations Blood 9 1954 514
151. M. Lee H. Kantarjian M. Talpaz Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome–positive chronic myelogenous leukemia following interferon therapy Blood 79 1992 1920
152. T. Leemhuis D. Leibowitz G. Cox Identification of BCR/ABL–negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow Blood 81 1993 801
153. T. Lion T. Henn A. Gaiger Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia Lancet 341 1993 275
154. H. Lissauer Zwei falle von leucaemie Klin Wochenschr 2 1865 403
155. F. Mahon M. Montastruc C. Fabères Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon Blood 84 1994 3592
156. F. Mahon C. Fabères J. Boiron High response rate using recombinant alpha interferon in patients with newly diagnosed chronic myeloid leukemia—analysis of predictive factors [abstract] Blood 88 suppl 1 1996 638a
157. A. Majlis H. Kantarjian T. Smith What is the significance of cytogenetic clonal evolution in patients with Philadelphia chromosome–positive chronic myelogenous leukemia [abstract] Blood 84 suppl 1 1994 150a
158. M. Malinge F. Mahon M. Delfau Quantitative determination of the hybrid bcr-abl RNA in patients with chronic myelogenous leukemia under interferon therapy Br J Haematol 82 1992 701
159. S. Marks R. McCaffrey D. Rosenthal Blastic transformation in chronic myelogenous leukemia: Experience with 50 patients Med Pediatr Oncol 4 1978 15
160. D. Marks J. Cullis K. Ward Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: A comparison of complications in the first two years Ann Intern Med 119 1993 207
161. BCR/ABL and inhibit the proliferation of bcr/abl–containing cell lines Blood 81 1993 502
162. J. Mason V. DeVita G. Cannelos Thrombocytosis in chronic granulocytic leukemia. Incidence and clinical significance Blood 44 1974 183
163. P. McGlave D. Arthur D. Weisdorf Allogeneic bone marrow transplantation as treatment for accelerating chronic myelogenous leukemia Blood 63 1984 219
164. P. McGlave De Fabritis P. A. Deisseroth Autologous transplants for chronic myelogenous leukemia: Results from eight transplant groups Lancet 343 1994 1486
165. P. McGlave Bone marrow transplants in chronic myelogenous leukemia: An overview of determinants of survival Semin Hematol 27 suppl 4 1990 23
166. Medical Research Council Randomised trial of splenectomy in Ph positive chronic granulocytic leukaemia including an analysis of prognostic features Br J Haematol 54 1983 415
167. J.V. Melo The diversity of bcr-abl fusion proteins and their relationship to leukemia phenotype Blood 88 1996 2375
168. J. Melo D. Gordon N. Cross The abl-bcr fusion gene is expressed in chronic myeloid leukemia Blood 81 1993 158
169. K. Mills P. Benn G. Birnie Does the breakpoint within the major cluster region influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature Blood 78 1991 1155
170. A. Nathwani J. Goldman The management of chronic myeloid leukemia in lymphoid blast crisis Haematologica 78 1993 162
171. A. Newland L. Jones M. Mir Alpha 2 interferon in chronic myeloid leukaemia following relapse post-allogeneic transplant Br J Haematol 66 1987 141
172. N. Niederle O. Kloke R. Osieka Interferon alfa-2b in the treatment of chronic myelogenous leukemia Semin Oncol 14 1987 29
173. P.C. Nowell D. Hungerford A minute chromosome in human chronic granulocytic leukemia Science 132 1960 1497
174. S. O'Brien H. Kantarjian M. Keating Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase Blood 86 1995 3322
175. S. O'Brien Guidelines for chronic myelogenous leukemia treatment with alpha interferon Leuk Lymphoma 23 1996 247
176. K. Ohnishi R. Ohno M. Tomonaga A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase Blood 86 1995 906
177. H. Oliner R. Schwartz F. Rubio Interstitial pulmonary fibrosis following busulfan therapy Am J Med 31 1961 134
178. T. Ordway Remission in leukemia produced by radium in cases completely resistant to x-ray and benzol treatment Boston Medical and Surgical Journal 176 1917 490
179. H. Ozer S. George C. Schiffer Prolonged subcutaneous administration of recombinant alfa-2b interferon in patients with previously untreated Philadelphia chromosome–positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583 Blood 82 1993 2975
180. G. Pap W. Arcese F. Mauro Standard conditioning regimens and T-cell depleted donor marrow for transplantation in chronic myeloid leukemia Leuk Res 10 1986 1469
181. L. Podoll S. Winkler Busulfan lung. Report of two cases and review of the literature Am J Roentgenol Radium Ther Nucl Med 120 1974 151
182. S.M. Podos G.P. Canellos Lens changes in chronic granulocytic leukemia: Possible relationship to chemotherapy Am J Ophthalmol 68 1969 500
183. D. Porter M. Roth C. McGarigle Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia N Engl J Med 330 1994 100
184. H. Preti S. O'Brien S. Giralt Philadelphia-chromosome–positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients Am J Med 97 1994 60
185. W. Pusey Report of cases treated with roentgen rays JAMA 38 1902 911
186. J. Quesada M. Talpaz A. Rios Clinical toxicity of interferons in cancer patients: A review J Clin Oncol 4 1986 234
187. M. Ratajczak N. Hijiya L. Catani Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides Blood 79 1992 1956
188. J. Reiffers R. Trouette G. Marit Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: A report of 47 cases Br J Haematol 77 1991 339
189. D. Renner U. Queisser C. Martinez Treatment of excessive thrombocytosis in chronic myeloid leukemia by thombocytopheresis and intravenous thiotepa Onkologie 10 1987 324
190. Report of the MRC Working Party Comparison of radiotherapy and busulfan therapy in chronic granulocytic leukemia Br Med J 1 1968 201
191. M. Robertson R. Tantravahi J. Griffin Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine Am J Hematol 43 1993 95
192. L. Ronnblom F. Alm K. Oberg Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors Ann Intern Med 115 1991 178
193. F. Rosner Z. Schreiber F. Parise Leukocyte alkaline phosphatase Arch Intern Med 130 1972 892
194. D. Ross R. Brunning H. Kantarjian A proposed staging system for chronic myeloid leukemia Cancer 71 1993 3788
195. M. Roth J. Antin R. Ash Prognostic significance of Philadelphia chromosome–positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia Blood 79 1992 276
196. J.D. Rowley A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa banding Nature 243 1973 290
197. D. Rushing A. Goldman G. Gibbs Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia Am J Clin Oncol 5 1982 307
198. G. Rustin J. Goldman D. McCarthy An extrinsic factor controls neutrophil alkaline phosphatase synthesis in chronic granulocytic leukaemia Br J Haematol 45 1980 381
199. S. Sacchi H. Kantarjian S. O'Brien Long-term follow-up results of alpha-interferon–based regimens in patients with late chronic phase chronic myelogenous leukemia [abstract] Blood 88 suppl 1 1996 201b
200. S. Sacchi H. Kantarjian P. Cohen Immune-mediated and unusual complications during alpha-interferon therapy in chronic myelogenous leukemia [abstract] Blood 84 suppl 1 1994 150a
201. J. Sanders C. Buckner R. Clift Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation Bone Marrow Transplant 3 1988 11
202. J. Schofield W. Robinson J. Murphy Low doses of interferon α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia Ann Intern Med 121 1994 736
203. D. Seong H. Kantarjian J. Ro Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome–positive cells in patients with chronic myelogenous leukemia during treatment Blood 86 1995 2343
204. P. Shepherd J. Fooks R. Gray Thioguanine used in maintenance therapy of chronic myeloid leukemia causes non-cirrhotic portal hypertension Br J Haematol 79 1991 185
205. R. Silver T. Szatrowski B. Peterson Combined α-interferon and low dose cytosine arabinoside for Ph+ chronic phase chronic myeloid leukemia [abstract] Blood 88 suppl 1 1996 638a
206. J. Sokal E. Cox M. Baccarani Prognostic discrimination in “good risk” chronic granulocytic leukemia Blood 63 1984 789
207. J. Sokal S. Leong G. Gomez Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia Cancer 59 1987 197
208. A. Spiers B. Bain J. Turner The peripheral blood in chronic granulocytic leukaemia: Study of 50 untreated Philadelphia positive cases Scand J Haematol 18 1977 25
209. R. Suri J. Goldman D. Catovsky Priapism complicating chronic granulocytic leukemia Am J Hematol 9 1980 295
210. M. Talpaz H. Kantarjian R. Kurzrock Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Ann Intern Med 114 1991 532
211. M. Talpaz G. Mavligit M. Keating Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia Ann Med Intern 99 1983 789
212. M. Talpaz H. Kantarjian J. Liang Percentage of Philadelphia chromosome–negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells Blood 85 1995 3257
213. M. Talpaz H. Kantarjian K. McCredie Clinical investigation of human alpha interferon in chronic myelogenous leukemia Blood 69 1987 1280
214. M. Talpaz H. Kantarjian K. McCredie Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia N Engl J Med 314 1986 1065
215. M. Talpaz H. Kantarjian I. Khouri Diploid cells collected from chronic myelogenous leukemia patients during recovery from conventional dose induced myelosuppression generate complete cytogenetic remissions after autologous transplantation [abstract] Blood 84 suppl 1 1994 537a
216. M. Talpaz H. Kantarjian R. Kurzrock Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia Cancer 69 1992 410
217. M. Talpaz Z. Estrov H. Kantarjian Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia J Clin Invest 94 1994 1383
218. M. Talpaz R. Kurzrock H. Kantarjian A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia Cancer 68 1991 2125
219. T. Terjanian H. Kantarjian M. Keating Clinical and prognostic features of patients with Philadelphia chromosome–positive chronic myelogenous leukemia and extramedullary disease Cancer 59 1987 297
220. J. Thaler T. Fluckinger H. Huber Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2c and low dose ara-c Leuk Res 17 1993 711
221. J. Thaler W. Hilbe U. Apfelbeck Interferon-alpha-2c and low dose ara-c for the treatment of patients with CML: Results of the Austrian multi-center phase II study Leuk Res 21 1997 75
222. S. Tura M. Baccarani G. Corbelli Staging of chronic myeloid leukaemia Br J Haematol 47 1981 105
223. G. Upadhyaya S. Guba S. Sih Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells J Clin Invest 88 1991 2131
224. N. Vey D. Baume M. Lafage Recombinant interleukin-2 induces cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase [abstract] Blood 88 suppl 1 1996 202b
225. R. Walters H. Kantarjian M. Keating Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and Adriamycin infusions plus high dose decadron Cancer 60 1987 1708
226. U. Wandl O. Kloke M. Nagel-Hiemke Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukemia Br J Haematol 81 1992 516
227. M. Wilhelm C. Ramos S. O'Brien Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia [abstract] Blood 88 suppl 1 1996 202b
228. D. Winfield S. Polacarz Bone marrow histology. 3: Value of bone marrow core biopsy in acute leukaemia, myelodysplastic syndromes, and chronic myeloid leukaemia J Clin Pathol 45 1992 855
229. A. Yuo S. Kitagawa T. Okabe Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia Blood 70 1987 404
230. L. Zhao H. Kantarjian Van Oort J. Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment Leukemia 7 1993 168